MSD today announced the acquisition of Rigontec for up to US$553M
by eazee-designstudio
The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom's innovation agency, Innovate UK. Themis will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate.
Immatics today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored trial using products consisting of autologous cytotoxic T lymphocytes targeting defined tumor antigens using Immatics’ novel and proprietary target warehouse.
A promising prophylactic vaccine candidate against Chikungunya fever will be tested from August on in a Phase II clinical study in Puerto Rico, a Chikungunya fever endemic area.
4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208.
Sponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S.
Rigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. In addition, Rigontec appoints industry veteran Prof. Eugen Leo as Chief Medical Officer.
The Supervisory Board of AYOXXA announces that following his initial assumption of the duties of CEO in October, Rodney Turner will continue to lead the company on a permanent basis
invendo medical Announces CE Mark for the invendoscope(TM) SC200, The World's First Sterile, Single-Use Endoscope For Colonoscopies
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
